EnVivo Pharmaceuticals, Inc. to Highlight Clinical Stage Program at Neuroscience 2011
10/31/2011 7:54:42 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it has been selected to discuss its lead program EVP-6124, a nicotinic alpha-7 agonist, at the Society for Neuroscience 41st Annual Meeting. Neuroscience 2011 will be held Nov. 12-16, 2011 at the Walter E. Washington Convention Center in Washington D.C.
comments powered by